EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combining Advanced Targeted Therapy in Inflammatory Bowel Disease: Current Practice and Future Directions

Alice De Bernardi, Cristina Bezzio iD, Michele Puricelli, Daniela Gilardi iD, Simone Saibeni iD

Journal of Clinical Medicine · 17.01.2025 · 14 (2) · 590

DOI: 10.3390/jcm14020590 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 17.01.2025. Verfasst von Alice De Bernardi und 4 weiteren Autor:innen. Beteiligte Einrichtung: IBD Unit, Gastroenterology Unit, Rho Hospital, ASST Rhodense, 20017 Rho, Italy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Despite the increasing number of available medications, a significant proportion of IBD patients fail to achieve the current therapeutic targets. Uncontrolled IBD has a significant impact on patients’ quality of life and on overall costs for the healthcare system. Given the complex pathophysiology of IBD, Combined Advanced Targeted Therapy (CATT), involving the combination of biologics/small molecules, appears to have biological plausibility and is gaining increasing interest. The aim of this narrative review is to provide the current evidence regarding CATT in IBD and propose future developments in this field.

Methods

Relevant literature evidence was searched with pertinent MeSH terms in the most important database.

Results

Available evidence of CATT in IBD provides encouraging results in terms of efficacy and effectiveness, with an acceptable safety profile. CATT may represent a therapeutic solution for patients with “difficult-to-treat” IBD or with concomitant immune-mediated inflammatory diseases. However, current data are restricted by an overall low level of evidence and by the short follow-up.

Conclusions

There are no data concluding the superiority of one combination therapy over another. Various therapeutic schemes could be applied in the near future. Further studies are needed to provide recommendations and integrate this therapeutic strategy into everyday clinical practice.

Schlagwörter

Stichwörter der Autor:innen

Crohn’s diseaseDual Targeted Therapybiologicscombined advanced therapyinflammatory bowel diseasesmall moleculestherapyulcerative colitis

Autor:innen und Institutionen

  • IBD Unit, Gastroenterology Unit, Rho Hospital, ASST Rhodense, 20017 Rho, Italy.
  • IBD Centre, IRCCS Humanitas, Research Hospital, 20089 Rozzano, Italy.
  • Department of Biomedical Sciences, Humanitas University, 20072 Milan, Italy.

ORCID-Profile: Cristina Bezzio, Daniela Gilardi, Simone Saibeni

Zitieren

APA

De Bernardi, A., Bezzio, C., Puricelli, M., Gilardi, D., & Saibeni, S. (2025). Combining Advanced Targeted Therapy in Inflammatory Bowel Disease: Current Practice and Future Directions. Journal of Clinical Medicine, 14(2), 590. https://doi.org/10.3390/jcm14020590

Vancouver

De Bernardi A, Bezzio C, Puricelli M, Gilardi D, Saibeni S. Combining Advanced Targeted Therapy in Inflammatory Bowel Disease: Current Practice and Future Directions. Journal of Clinical Medicine. 2025;14(2):590. doi:10.3390/jcm14020590

BibTeX
@article{DeBernardi2025,
  author = {De Bernardi, Alice and Bezzio, Cristina and Puricelli, Michele and Gilardi, Daniela and Saibeni, Simone},
  title = {Combining Advanced Targeted Therapy in Inflammatory Bowel Disease: Current Practice and Future Directions},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {2},
  pages = {590},
  doi = {10.3390/jcm14020590}
}
Kostenlos starten →